Editors’ Picks

Cutaneous squamous cell carcinoma (SCC) has the clinical and molecular features of a tumor that is likely to respond to systemic immunotherapy, as this tumor harbors a high mutational load and incidence is increased in immunocompromised patients. While nearly all cases are cured with surgery, in the remaining 5%, the tumor becomes metastatic or locally advanced, requiring palliative systemic therapy due to a lack of efficacious approved systemic therapies. In early phase I trials, the human monoclonal antibody to programmed death-1 (PD-1), cemiplimab, elicited a durable response in patients with advanced disease.